Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria

Trial Profile

A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RTX-134 (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Sponsors Rubius Therapeutics
  • Most Recent Events

    • 14 Nov 2019 According to a Rubius Therapeutics media release, the company has successfully manufactured RTX-134 fro this trial.
    • 14 Nov 2019 According to a Rubius Therapeutics media release, the company expect to report initial clinical results during the first quarter of 2020.
    • 27 Sep 2019 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top